Sinopia Biosciences
The AI engine Fit Assessment
BetaSinopia Biosciences effectively leverages machine learning and multi-omics data to discover new patterns and expand therapeutic options, optimizing the drug discovery process.
Blurb
Sinopia Biosciences enables data-driven drug discovery by means of multi-omics data, machine learning, network analyses, and disease models.
HQ Location
San Diego (United States)
Founded
2014
Employees
1 - 10
Total funding raised
$16.61M
Last Funding Event
Grant, $2.20M, September 12, 2024
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Drug Discovery Optimization
Sinopia Biosciences is transforming drug discovery and illness research. For the past thirty years, target-based drug discovery has been the predominant method. However, phenotypic screening has shown greater productivity in the discovery of first-in-class medications due to the fact that the pathogenesis of many diseases is often complex and the etiology of many diseases is unclear.